Acrivon Therapeutics Inc. has announced upcoming presentations of preclinical and initial clinical data for its novel candidate ACR-2316 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, MA. The data will highlight the company's proprietary Generative Phosphoproteomics AP3 platform, including the AP3 KaiSR ensemble model, which is used to optimize drug design for specific pathway effects in tumor cells. Preclinical results have demonstrated differentiated and superior pathway effects of ACR-2316 compared to benchmark WEE1 and PKMYT1 inhibitors. Initial clinical data from the ongoing Phase 1 study, including observed clinical activity and a confirmed partial response during dose escalation in AP3-predicted solid tumor types, will be reported later this year. The posters will be available on Acrivon's website following their presentation at the conference.